Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
AssigneeUniversiteit Van Amsterdam
InventorsMarten Piet SMIDT, Lars Philip VAN DER HEIDE
Life of this patent
Estimating the term…
Abstract
In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a PDE2 inhibitor, a PDE11 inhibitor or a combination thereof, optionally together with a GUCY2C agonist.
Claims12
1-7. (canceled)
A method of increasing phosphorylation of the serine residue at position 40 of human tyrosine hydroxylase (S40 Th) by a dopaminergic cell, the method comprising contacting said cell with a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof
A method of increasing dopamine production by a dopaminergic cell, the method comprising contacting said cell with a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof
A method of treatment of an individual that has Parkinson's disease, or is at risk of developing the disease, the method comprising administering a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof to the individual in need thereof.
A GUCY2C agonist comprising the sequence NDDCELCVNVACTGCLL;
- NDCCELCCNVACTGCL;
- NDDCELCVNVVCTGCL;
- QEECEL[Abu]INMACTGY;
- QEECELCINMACTGCL;
- NTFYCCELCCNPACAGCY;
- NTFYCCELCCAPACTGCY;
- or NTFYCCELCCNPaCAGCY.
The method of claim, wherein the GUCY2C agonist is guanylin or a functional derivative thereof.
Dependencies are inferred from the claim text.